Sun Pharma's IL-23 inhibitor tildrakizumab gains a psoriatic arthritis indication; the announcement cited no phase 3 efficacy figures.
|Articles|July 1, 2001
- Pharmaceutical Executive-07-01-2001
- Volume 0
- Issue 0
Submerged
Author(s)Wayne Koberstein
Is the pharmaceutical industry surrounded by its critics? Can the industry be liberated from the moral bind others want to impose on it? Those are questions I asked and attempted to answer in two recent editorials (PE April and June 2001). Actually, the simple answer was yes to both. But other answers prove more complex.
Advertisement
Articles in this issue
over 25 years ago
Pharmacies: OTC Price Warsover 25 years ago
One Disease at a Timeover 25 years ago
Overview of the Industry: A World of Opportunitiesover 25 years ago
The Power Shiftover 25 years ago
A Giant Stumblesover 25 years ago
Overruled: No More Dual Pricingover 25 years ago
Generic ThreatAdvertisement
Related to this article
Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.
Shionogi’s Dr. Draica on why mild COVID-19 still matters, how XOCOVA blocks replication before symptoms, and why prevention beats treatment.
Earlier pediatric planning, innovative trial design, and closer collaboration among regulators, industry, and families are needed to close the persistent gap between the evidence available for adult and pediatric treatments.
BioMarin licenses long-acting Fabry enzyme replacement therapy HM15421/GC1134A, while Ferring agrees to acquire fertility biotech Gameto.
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
Shionogi’s Dr. Draica on why mild COVID-19 can worsen chronic conditions for up to a year — and why prevention matters more than hospitalization data suggests.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion
2
Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial
3
How Preventative Medications May Impact the Lingering Impact of COVID-19
4
FDA Approves Ilumya for Adults With Active Psoriatic Arthritis
5